2018 American Transplant Congress
Eluates from Fine-Needle Allograft Biopsy Increase Donor-Specific Antibody Identification in Antibody Mediated Rejection
1University of Cincinnati, Cincinnati; 2Hoxworth Blood Center, Cincinnati.
Aim. Antibody mediated rejection (AMR) represents a risk for graft loss, and the presence of circulating donor-specific antibody (cDSA) is a major criterion for AMR…2018 American Transplant Congress
Late Donor-Specific Antibody (Especially Class II) Development is Associated with an Increased Risk for Cardiac Allograft Vasculopathy
Cedars Sinai Medical Center, Los Angeles.
Purpose: Development of donor-specific antibodies (DSA) following heart transplantation (HTx) impacts rejection, cardiac allograft vasculopathy (CAV), and survival. In addition, the timing of Ab development…2018 American Transplant Congress
Evaluation of Immunosuppression and Infection after Desensitization in Lung Transplantation
University of Maryland Medical Center, Baltimore.
Purpose: To reduce waitlist time for sensitized lung transplant recipients (LTR), our center used peri-operative desensitization for LTR with a positive virtual crossmatch (P-VXM). We…2018 American Transplant Congress
Genetically Modified Porcine Erythrocytes: A Cell Model for Studying Human Preformed Antibody-Dependent Xenoimmune Responses In Vitro
Surgery, University of Alabama at Birmingham, Birmingham, AL.
Background: Powerful gene editing technology is a promising approach to provide genetically-modified pigs as donors for clinical cell, tissue and organ xenotransplantation. Prior to starting…2018 American Transplant Congress
A Follow-Up Report on the Use of IVIG+Rituximab to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly-Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) with IVIG/rituximab is associated with a reduction in donor specific antibodies (DSA), improved transplant rates and outcomes in highly-sensitized (HS) patients. We…2018 American Transplant Congress
Clinical Response to Salvage Bortezomib Therapy for Antibody Mediated Rejection and Mixed Acute Rejection in a High Immunologic Risk Renal Transplant Population
University of Illinois at Chicago, Chicago, IL.
Background: Proteasome inhibitor (PI) containing regimens treat antibody mediated rejection (AMR) and mixed acute rejection (MAR) due to elimination of donor specific antibody (DSA). Commonly,…2018 American Transplant Congress
Sharing Works; Avoiding Kidney Transplantation to an Unintended Recipient by Precision Virtual Cross Match with Excellent Outcomes
1UCSF, San Francisco; 2Donor Network West, San Ramon.
Aim: It was recently estimated that 19.2% of imported kidneys go into an unintended recipient(UR), most commonly due to a positive crossmatch(AJT 2017, 17:2139) so…2018 American Transplant Congress
Evaluation of Hepatitis B Vaccination in Transplant Candidates
Background:Hepatitis B virus (HBV) vaccine series is recommended for all organ transplant candidates; high doses of vaccine are generally given to those with renal disease;…2018 American Transplant Congress
Type I NKT Cells Augment Humoral and Cellular Alloimmunity in Response to Hepatocyte Transplantation
Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
Hepatocyte transplantation (HcTx) is a potential therapeutic modality for patients with liver disease. Despite examples of antigen acceptance in the liver, allogeneic HcTx into patients…2018 American Transplant Congress
modified DFPP Can Eliminate Donor-Reactive IgG Antibody with Preserving Fibrinogen before Kidney Transplantation
BACKGROUND: Elimination of preexisting IgG antibodies against donor antigen is an important role before antibody-incompatible (i.e. ABO-incompatible and donor-specific antibody positive) kidney transplantation. Plasma exchange…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 57
- Next Page »